FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
56 letters match. Newest first.
-
DrugsSignature Formulations, LLC
FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.
High risk -
DrugsHTO Nevada, Inc. dba Kirkman
HTO Nevada dba Kirkman, an OTC drug contract manufacturer, was cited for CGMP violations including mislabeled reformulated drugs.
High risk -
DrugsFulijaya Manufacturing SDN. BHD.
Fulijaya Manufacturing in Malaysia failed CGMP (drug manufacturing rules) for OTC drugs, with missing lab data, flawed microbial tests, and weak stability data.
High risk -
DrugsTower Laboratories Ltd.
FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.
High risk -
DrugsLiquidCapsule Manufacturing, LLC
LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.
High risk -
DrugsPrivate Label Skin Care, Inc.
FDA warned Private Label Skin Care about poor quality oversight, continued sale of impurity-affected over-the-counter drugs, and missing drug listings.
High risk